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Objectives The aim of this study was to analyze the relationship between payment source and quality of care and outcomes
in heart failure (HF).
Background HF is a major cause of morbidity and mortality. There is a lack of studies assessing the association of payment
source with HF quality of care and outcomes.
Methods A total of 99,508 HF admissions from 244 sites between January 2005 and September 2009 were analyzed.
Patients were grouped on the basis of payer status (private/health maintenance organization, no insurance,
Medicare, or Medicaid) with private/health maintenance organization as the reference group.
Results The no-insurance group was less likely to receive evidence-based beta-blockers (adjusted odds ratio [OR]: 0.73;
95% confidence interval [CI]: 0.62 to 0.86), implantable cardioverter-defibrillator (OR: 0.59; 95% CI: 0.50 to
0.70), or anticoagulation for atrial fibrillation (OR: 0.73; 95% CI: 0.61 to 0.87). Similarly, the Medicaid group was
less likely to receive evidence-based beta-blockers (OR: 0.86; 95% CI: 0.78 to 0.95) or implantable cardioverter-
defibrillators (OR: 0.86; 95% CI: 0.78 to 0.96). Angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers and beta-blockers were prescribed less frequently in the Medicare group (OR: 0.89; 95% CI: 0.81 to
0.98). The Medicare, Medicaid, and no-insurance groups had longer hospital stays. Higher adjusted rates of in-
hospital mortality were seen in patients with Medicaid (OR: 1.22; 95% CI: 1.06 to 1.41) and in patients with re-
duced systolic function with no insurance.
Conclusions Decreased quality of care and outcomes for patients with HF were observed in the no-insurance, Medicaid, and
Medicare groups compared with the private/health maintenance organization group. (J Am Coll Cardiol 2011;
58:1465–71) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.034Heart failure (HF) is a major cause of morbidity and
mortality and places a significant economic drain on the
health care system (1). Mortality from HF is higher in
patients with reported lower socioeconomic status (2).
However, there is a lack of evidence to explain this obser-
vation. Potential disparities in the quality of health care
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accepted June 27, 2011.might account for these findings, but data from the few
small studies that exist are inconsistent, with some studies
showing a possible association with poorer quality of care
and adverse outcomes (3) and other studies failing to
replicate these findings (4). Prior studies also suggest that
patients with HF with different types of health insurance
may receive different treatment, which may result in differ-
ences in short- and long-term outcomes (2,3). Currently,
there are no consistent data that differences in quality of
See page 1472
care on the basis of a patient’s health insurance exist in the
realm of inpatient management and follow-up care in patients
hospitalized with HF. Determining possible differences in
quality of care and outcomes in patients by insurance type is
warranted to develop interventions aimed at improving adher-
ence to HF quality-of-care measures and outcomes.
The Get With the Guidelines Heart Failure (GWTG-HF)
program prospectively tracks several performance measures
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tors for patients hospitalized
with HF (5,6). In this study, we
sought to investigate HF quality-
of-care measures, length of hos-
pital stay, and in-hospital mor-
tality stratified by type of health
insurance. The goal was to deter-
mine the association of payment
status with health care quality
and in-hospital outcomes in a
contemporary database to iden-
tify potential targets to achieve
reductions in health disparities
and improve outcomes.
Methods
Data collection. As previously
described (7,8), the GWTG-HF
program is a national, prospec-
tive, observational and ongoing voluntary clinical registry
and continuous quality improvement initiative. The registry
enrolls adults hospitalized with episodes of new or worsen-
ing HF as the primary reason for admission or with
significant HF symptoms that developed during hospital-
ization for which HF was the primary discharge diagnosis.
Participating hospitals are from all census regions of the
U.S. and include teaching and nonteaching, rural and urban,
and large and small hospitals.
Clinical information about consecutive eligible patients is
submitted by participating institutions online using an
interactive case report form in compliance with Joint Com-
mission and Centers for Medicare and Medicaid Services
standards. Outcome Sciences, Inc. (Cambridge, Massachu-
setts), serves as the data collection and coordination center
for GWTG. Clinical data are abstracted using standardized
definitions; variables collected include demographic and
clinical characteristics, medical history, previous treatments,
contraindications to therapies, and outcomes. Checks are
performed to ensure that the reported data are complete and
that the accuracy of data quality is monitored. Participants’
institutional review boards review and approve the GWTG
protocol. Sites were granted a waiver of informed consent
under the common rule because data were used primarily at
the local sites for quality improvement. The Duke Clinical
Research Institute serves as the data analysis center.
Study population. The population for this study consisted
of 106,351 HF admissions from 249 fully participating sites
between January 2005 and September 2009. Patients were
excluded if they were missing data on payment source (n 
5,916) or mortality (n  927). This left a study cohort of
99,508 at 244 sites. Data were stratified into groups by
payment source (Medicare, Medicaid, no insurance, and
private/health maintenance organization [HMO]). Patients
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
CI  confidence interval
EF  ejection fraction
GWTG-HF  Get With the
Guidelines Heart Failure
HF  heart failure
HMO  health maintenance
organization
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LVSD  left ventricular
systolic dysfunction
OR  odds ratiowith Medicare along with private/HMO insurance wereclassified as private/HMO. Patients with Medicaid and
Medicare were classified as Medicaid.
Outcome measures. The main pre-specified quality-of-
care outcomes that were measured include the core measures
used by the Centers for Medicare and Medicaid Services
and the Joint Commission (8,9), as follows: 1) complete
discharge instructions; 2) documented evaluation of left
ventricular function before arrival, during hospitalization, or
planned after discharge; 3) angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs)
for patients with HF with left ventricular systolic dysfunc-
tion (LVSD) without contraindications or intolerance; and
4) adult smoking cessation advice or counseling for patients
with histories of smoking cigarettes. An additional
GWTG-HF measure of any beta-blocker use at discharge
for patients with LVSD without contraindications or intol-
erance was also included. Patients with documented con-
traindications were excluded from quality measures. Two
composite measures established by the GWTG-HF pro-
gram were also assessed. One was a composite quality
measure—an opportunity quality-of-care index—that was
based on the number of therapeutic interventions in relation
to the circumstances when those interventions were indi-
cated for the 5 measures (number of successes with quality
measure/number eligible for quality measure). The other
composite measure was an all-or-none measure for 100%
compliance with all 5 quality measures (whether eligible
patients received 100% of guideline-based therapy, up to a
maximum of all 5 measures). Additional quality measures of
interest included: 1) anticoagulant therapy at discharge for
patients with atrial fibrillation; 2) aldosterone antagonists
prescribed at discharge for patients with LVSD; 3) hydral-
azine nitrates in African American patients with LVSD;
4) evidence-based specific beta-blocker (carvedilol, meto-
prolol succinate, or bisoprolol fumarate) prescribed at dis-
charge for patients with LVSD; 5) implantable cardioverter-
defibrillators (ICDs) placed or prescribed at discharge for
patients with left ventricular ejection fractions (EFs)30%;
and 6) ACE inhibitors or ARBs and beta-blockers for
patients with LVSD at discharge. In the subgroup from
2009, the use of deep venous thrombosis prophylaxis and
administration of the influenza and pneumococcal vaccina-
tions were also assessed. Finally, length of hospital stay
(number of days from admission to discharge) and in-
hospital deaths were also assessed.
Statistical analysis. Baseline characteristics were compared
across payment source groups using the Pearson chi-square
test for categorical variables and the Kruskal-Wallis test for
continuous variables. Categorical variables are reported as
percents and continuous variables as median (interquartile
range [IQR]). Multivariate logistic regression was per-
formed using the generalized estimating equations methods
to adjust for clustering within hospitals to determine
whether payment source independently influenced each
outcome and quality-of-care measure. Private/HMO was
the reference group. Log transformation was used for the
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distribution. Models were adjusted for patient characteris-
tics and medical history and hospital characteristics. A p
value 0.05 was considered significant for all tests. All
nalyses were performed using SAS version 9.2 (SAS
nstitute, Inc., Cary, North Carolina).
esults
aseline characteristics. The total study cohort consisted
f 99,508 patients hospitalized with diagnoses of HF, of
hom 45,353 (45.6%) had documented reduced EFs,
7,779 (48.0%) had preserved EFs, and 6,376 (6.4%) did
ot have EFs documented. There were 28,702 patients
28.8%) documented to have private/HMO insurance,
5,103 (55.4%) with Medicare, 10,684 (10.7%) with Med-
caid, and 5,019 (5.0%) who were uninsured or without
nsurance type documented. The baseline characteristics of
he overall population stratified by insurance group are
resented in Table 1. The median age of the overall
opulation was 75 years (IQR: 62 to 83 years), with the
ldest population seen in the Medicare group (median 78
ears; IQR: 70 to 85 years) and the youngest population
een in the group with no insurance (median 53 years; IQR
6 to 61 years). Overall, this was a predominantly white
opulation (68%), with more black HF patients seen in the
edicaid and no-insurance groups. There were also equal
roportions of female and male patients in the overall
opulation, but across groups, there were differences, with
igher relative proportions of female patients seen in the
edicaid and Medicare groups, whereas more male patients
ere seen in the private/HMO and no-insurance groups.
Baseline Characteristics in the Overall Population and by PaymentTable 1 Baseline Characteristics in the Overall Population and
Characteristic
Total
(n  99,508)
Private/HMO/Othe
(n  28,702)
Age (yrs) 75 (62–83) 71 (59–82)
Women 48.7 44.8
Race
White 67.7 69.4
Hispanic 6.2 5.0
Black/other 23.1 22.2
History
Anemia 17.6 15.4
Atrial fibrillation/atrial flutter 31.1 29.7
CAD 48.1 46.2
Ischemic etiology 54.7 52.8
COPD or asthma 29.1 26.0
CVA or TIA 13.9 11.8
Depression 9.5 8.7
Dialysis 10.8 10.6
Diabetes 41.8 41.2
PVD 11.6 10.5
Hypertension 74.9 73.1
Renal insufficiency 20.2 18.4
Values are median (interquartile range) or %.
CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease; CVA  cerebrovascul
transient ischemic attack.Although the Medicare group had more anemia, coronary
artery disease (including an ischemic etiology), cerebrovas-
cular accident or transient ischemic attack, peripheral vas-
cular disease, and renal insufficiency, those with Medicaid
had more chronic obstructive pulmonary disease or
asthma, diabetes, and hypertension. Overall, the no-
insurance group had the lowest prevalence of comorbidi-
ties, except for hypertension. In addition, greater propor-
tions of the Medicaid and no-insurance groups were
treated at academic hospitals and at hospitals with
intervention, percutaneous coronary intervention, or sur-
gery availability (Online Table 1).
Payment source and quality of care. Adherence to per-
formance and quality measures varied by payment source
(Online Table 2). When the cohort with LVSD was
considered, the group with no insurance had the highest
proportions of prescriptions for many evidence-based ther-
apies (e.g., ACE inhibitors or ARBs at discharge and
beta-blockers), while the lowest proportions were seen in
patients with Medicare. Similarly, high use of evidence-
based management in patients with no insurance pertained
to discharge instructions, smoking cessation, the use of
aldosterone antagonists, anticoagulation for atrial fibrilla-
tion, deep venous thrombosis prophylaxis, and the 100%
compliance measure compared with all other groups. How-
ever, the lowest proportions of either ICD placement or a
prescription for an ICD at discharge was detected in the
no-insurance and Medicaid groups (31% and 38%, respec-
tively), and the highest proportions were detected in the
Medicare (42%) and private/HMO (41%) groups (p 
.0001 for all groups). Finally, the lowest rates of influenza
ceayment Source
Medicaid
(n  10,684)
Medicare
(n  55,103)
No Insurance
(n  5,019) p Value
62 (53–75) 78 (70–85) 53 (46–61) 0.0001
54.4 51.0 34.4 0.0001
0.0001
37.7 75.5 34.8
11.8 5.2 12.7
47.2 16.5 48.6
16.1 19.7 10.0 0.0001
21.6 35.4 12.2 0.0001
41.9 52.2 28.2 0.0001
48.0 58.9 32.8 0.0001
34.0 30.5 21.7 0.0001
14.7 15.4 7.1 0.0001
10.6 10.1 5.5 0.0001
11.7 11.0 8.3 0.0001
47.3 41.7 33.9 0.0001
9.4 13.3 3.7 0.0001
78.0 75.1 75.2 0.0001
20.2 21.9 12.2 0.0001Sourby P
rar accident; HMO  health maintenance organization; PVD  peripheral vascular disease; TIA 
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aid and no-insurance groups.
Adjusted quality of care according to payment source.
Differences in quality of care according to payment source
persisted after generalized estimating equations multivariate
regression analyses accounting for common patient and
hospital characteristics and clustering of patients within
hospitals (Table 2). For example, compared with the pri-
vate/HMO group, the no-insurance group was less likely to
receive anticoagulation for atrial fibrillation (odds ratio
[OR]: 0.73; 95% confidence interval [CI]: 0.61 to 0.87),
evidence-based specific beta-blockers for LVSD (OR: 0.73;
95% CI: 0.62 to 0.86), or ICD implantation or planned
implantation in appropriate candidates (OR: 0.59; 95% CI:
0.50 to 0.70). Patients with no insurance were more likely to
receive discharge instructions and smoking cessation coun-
seling. The Medicaid group was also less likely to receive
ACE inhibitors or ARBs and beta-blockers (OR: 0.89; 95%
CI: 0.79 to 0.99) and similarly less likely to receive
evidence-based specific beta-blockers (OR: 0.86; 95% CI:
0.78 to 0.95) or ICDs for LVSD (OR: 0.86; 95% CI: 0.78
to 0.96). Finally, the Medicare group was less likely to
receive ACE inhibitors or ARBs (OR: 0.85; 95% CI: 0.76
to 0.95) or the composite of an ACE inhibitor or ARB and
a beta-blocker (OR: 0.89; 95% CI: 0.81 to 0.98).
Payment source and length of hospital stay. After mul-
tivariate adjustment, compared with the private/HMO
group, there were longer associated hospital stays in the
Medicare, Medicaid, and no-insurance groups (Table 3).
There were also longer associated hospital stays after ad-
justment in patients on Medicaid, those on Medicare, and
those with no insurance compared with the private/HMO
group among patients with preserved systolic function and
in patients on Medicare and those with no insurance among
patients with LVSD (Online Table 4).
Payment source and in-hospital mortality. There were
2,944 in-hospital deaths (3.0%) during the study (Online
Table 2). After multivariate adjustment for patient charac-
teristics and laboratory values, a higher overall mortality rate
was seen in the Medicaid group (OR: 1.22; 95% CI: 1.06 to
1.41) (Table 3). A higher rate of in-hospital mortality was
again seen in the Medicaid group in patients with preserved
EFs and in the no-insurance group in patients with LVSD
(Online Table 4).
Discussion
Among hospitals participating in GWTG-HF, we found
significant differences in the application of evidence-
based care and in-hospital outcomes by payment source
in this large contemporary cohort of patients hospitalized
with HF throughout the U.S. Specifically, higher ad-
justed rates of in-hospital mortality were seen in patients
with Medicaid and in patients with no insurance (in the
group with LVSD). Similarly, compared with patients
with private/HMO insurance, longer HF hospitalizationadjusted length of stay was seen in patients with Medic-
aid, those with Medicare, and those with no insurance. In
addition, compared with patients with private/HMO
insurance, we found that patients with no insurance,
Medicaid, or Medicare less often received some of the
guideline-recommended therapies that are currently in-
cluded in the HF performance and quality measures.
After adjustment for potential confounders, there was
lower use of the composite of ACE inhibitors or ARBs
and beta-blockers in patients on Medicare and Medicaid.
Patients with Medicaid were also less likely to receive
smoking cessation instructions, evidence-based specific
beta-blockers for LVSD, and ICDs in eligible patients.
Having no insurance was similarly associated with lower
use of anticoagulation for atrial fibrillation or evidence-
based beta-blockers for LVSD and a decrease in the odds
of receiving ICDs in eligible patients. Interestingly,
patients without insurance were more likely to receive
discharge instructions and smoking cessation counseling.
Medicare patients were most likely to receive ICD
placement, which may reflect the financial impact of ICD
placement in patients without insurance or with Medic-
aid on providers. These findings suggest that even among
hospitals participating in a national quality improvement
program, HF patients’ insurance status is still associated
with the care provided and clinical outcomes in the
inpatient setting.
Despite major advances in HF treatments, access to
evidence-based care may be limited by patients’ insurance
status. Limitations in or complete lack of health insurance may
influence access to and delivery of care. However, there is a lack
of studies assessing this in patients with HF. One study
demonstrated a significantly higher admission rate in a man-
aged care cohort compared with groups with other payment
sources (10). However, there was no association between
managed care and poor short-term outcomes of hospital-
ization. Our study adds significant insight demonstrating
that insurance status is significantly associated with the use
of guideline-recommended HF therapies and in-hospital
clinical outcomes in a very large contemporary cohort of
patients with HF.
Smaller studies of other populations have reported dis-
parities in health care quality and outcomes on the basis of
socioeconomic status (3). Studies have demonstrated a link
between socioeconomic inequalities and cardiovascular dis-
ease mortality (11) and a decreased likelihood of receiving
regular medical care (12). Although insurance status is not
synonymous with socioeconomic status, they are inter-related.
There is a lack of studies assessing the association of socio-
economic status and/or payer status with HF quality of care
and outcomes, and a few small studies have yielded oppos-
ing findings. Higher associated readmission rates were
demonstrated among lower socioeconomic groups in other
studies (13). However, findings from other studies on HF
are inconsistent, with some failing to demonstrate an
association between socioeconomic status and outcomes (4).
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Univariate Multivariate
Measure Insurance Private/HMO/Other p Value Private/HMO/Other* p Value
Performance
ACE inhibitors or ARBs for LVSD at discharge Medicaid 0.92 (0.82–1.03) 0.13 0.88 (0.77–1.00) 0.052
Medicare 0.74 (0.68–0.81) 0.0001 0.85 (0.76–0.95) 0.0032
None/UTD 1.31 (1.18–1.45) 0.0001 1.09 (0.96–1.24) 0.20
Beta-blockers (any) for LVSD at discharge Medicaid 1.00 (0.91–1.10) 0.96 0.95 (0.84–1.08) 0.42
Medicare 0.88 (0.81–0.96) 0.0037 0.98 (0.88–1.10) 0.79
None/UTD 1.10 (0.95–1.26) 0.20 0.96 (0.79–1.17) 0.70
Discharge instructions Medicaid 0.93 (0.87–0.99) 0.022 0.94 (0.87–1.02) 0.12
Medicare 0.97 (0.92–1.01) 0.13 0.96 (0.90–1.03) 0.25
None/UTD 1.09 (1.01–1.18) 0.025 1.13 (1.03–1.25) 0.014
LV function assessed Medicaid 0.91 (0.85–0.96) 0.0009 0.83 (0.73–0.93) 0.0016
Medicare 0.84 (0.79–0.89) 0.0001 0.78 (0.69–0.89) 0.0002
None/UTD 1.08 (0.99–1.17) 0.082 1.06 (0.87–1.30) 0.57
Smoking cessation Medicaid 0.86 (0.77–0.96) 0.0095 0.80 (0.67–0.95) 0.012
Medicare 0.84 (0.77–0.92) 0.0001 0.86 (0.74–0.98) 0.029
None/UTD 1.24 (1.12–1.37) 0.0001 1.28 (1.08–1.53) 0.0057
Composite score (%) (number of successes/number eligible) Medicaid 90.04 21.39 0.0085 0.0050
Medicare 90.55 21.88 0.0001 0.0096
None/UTD 93.87 15.37 0.0001 0.0020
Private/HMO/other 91.16 20.29
100% compliance Medicaid 0.93 (0.88–0.99) 0.025 0.94 (0.88–1.01) 0.11
Medicare 0.96 (0.91–1.01) 0.11 0.92 (0.86–0.99) 0.020
None/UTD 1.01 (0.95–1.09) 0.68 1.09 (1.01–1.19) 0.036
ACE inhibitors or ARBs and beta-blockers for LVSD at discharge Medicaid 0.94 (0.85–1.03) 0.16 0.89 (0.79–0.99) 0.049
Medicare 0.78 (0.72–0.85) 0.0001 0.89 (0.81–0.98) 0.022
None/UTD 1.21 (1.09–1.35) 0.0003 1.04 (0.90–1.20) 0.58
Quality
Aldosterone antagonists for LVSD at discharge Medicaid 1.11 (1.01–1.22) 0.025 0.99 (0.91–1.08) 0.88
Medicare 0.80 (0.75–0.85) 0.0001 0.97 (0.91–1.03) 0.33
None/UTD 1.13 (0.99–1.29) 0.064 0.97 (0.86–1.09) 0.62
Anticoagulation for atrial fibrillation Medicaid 0.75 (0.67–0.85) 0.0001 0.74 (0.65–0.83) 0.0001
Medicare 0.80 (0.74–0.87) 0.0001 0.94 (0.87–1.01) 0.092
None/UTD 0.96 (0.81–1.13) 0.59 0.73 (0.61–0.87) 0.0003
DVT prophylaxis (2009 only) Medicaid 1.03 (0.90–1.19) 0.64 1.00 (0.87–1.15) 0.99
Medicare 1.02 (0.91–1.14) 0.76 1.04 (0.92–1.17) 0.58
None/UTD 1.00 (0.81–1.23) 0.98 0.96 (0.78–1.18) 0.71
Evidence-based specific beta-blockers for LVSD Medicaid 0.91 (0.83–1.00) 0.042 0.86 (0.78–0.95) 0.0040
Medicare 0.88 (0.83–0.93) 0.0001 0.97 (0.91–1.04) 0.42
None/UTD 0.79 (0.67–0.92) 0.0026 0.73 (0.62–0.86) 0.0002
Hydralazine and isosorbide dinitrate for African Americans at
discharge
Medicaid 1.01 (0.87–1.16) 0.93 1.01 (0.87–1.18) 0.85
Medicare 1.11 (0.97–1.28) 0.12 1.04 (0.91–1.20) 0.55
None/UTD 0.97 (0.77–1.22) 0.78 1.01 (0.82–1.25) 0.90
ICDs placed or prescribed at discharge Medicaid 0.87 (0.78–0.97) 0.013 0.86 (0.78–0.96) 0.0075
Medicare 0.92 (0.85–0.99) 0.025 1.06 (0.98–1.14) 0.17
None/UTD 0.57 (0.47–0.70) 0.0001 0.59 (0.50–0.70) 0.0001
Influenza vaccination during flu season (2009 only) Medicaid 0.99 (0.92–1.05) 0.70 0.99 (0.92–1.05) 0.69
Medicare 1.02 (0.97–1.07) 0.37 1.02 (0.96–1.08) 0.49
None/UTD 1.05 (0.93–1.18) 0.45 1.07 (0.95–1.20) 0.29
Pneumococcal vaccination (2009 only) Medicaid 1.01 (0.94–1.09) 0.81 1.01 (0.93–1.09) 0.89
Medicare 1.05 (1.00–1.10) 0.036 1.04 (0.99–1.10) 0.091
None/UTD 1.04 (0.91–1.20) 0.58 1.05 (0.92–1.21) 0.45
Values are OR (95% CI) or mean  SD. *All multivariate models were adjusted for patient characteristics (age, race, sex, admission systolic blood pressure, heart rate, history of anemia, stroke history,
diabetes, chronic obstructive pulmonary disease, hypertension, atrial fibrillation or flutter, peripheral vascular disease, renal failure, depression, smoking status, and etiology of heart failure) and hospital
characteristics (region; number of beds; academic status; and heart transplantation, surgical, and percutaneous coronary intervention capability).ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CI  confidence interval; DVT  deep venous thrombosis; HMO  health maintenance organization; ICD  implantable
ardioverter-defibrillator; LV  left ventricular; LVSD  left ventricular systolic dysfunction; OR  odds ratio; UTD  unable to determine; other abbreviations as in Table 1.
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to be higher in those with lower socioeconomic status,
but there is little evidence to explain this observation (2).
It has been proposed that uncorrected risk factors such as
smoking, hypertension, coronary artery disease, and dia-
betes mellitus in the lower socioeconomic groups may
account for this finding (13). Indeed, several of these
factors are seen more often in lower socioeconomic
groups, supporting this notion (14). However, differences
among groups were seen after multivariate analyses in our
study adjusting for many of these factors. Another
possibility is that differences in the implementation of
guideline-endorsed HF therapy, as we saw in this study,
may in part explain this observation. Our data demon-
strate that significant differences exist in the implemen-
tation of guideline-endorsed HF therapy and outcomes
according to payer status, with decreased quality and
outcomes in patients with no insurance, Medicaid, and
Medicare compared to the private/HMO group. A bias
not to prescribe drugs or therapies with lifesaving benefits
to certain groups can certainly perpetuate the observed
increases in HF prevalence and poor outcomes. The
reasons for disparate prescribing behavior on the basis of
payer status are unknown. Access inequalities to specialist
care during hospital admissions may explain some of the
differences (3). One study demonstrated an increased rate
of rehospitalization in patients with HF with lower
socioeconomic status that was independent of disease
severity, suggesting that socioeconomic status may influ-
ence the clinical management of HF (13). The same
study also showed that the increased rate of rehospital-
ization was independent of noncompliance with diuretic
agents, arguing, at least in the case of diuretic agents,
against medication noncompliance as a reason for in-
creased morbidity in patients with lower socioeconomic
status. The reasons behind the disparities warrant further
investigation to help mitigate associated poorer outcomes
in patients with lower socioeconomic status. Finally, it is
unclear how the quality of health care and outcomes will
be affected in the era of health care reform that is
expected to expand insurance coverage to more Ameri-
Univariate and Multivariable Models of In-Hospital Outcomes by PaTable 3 Univariate and Multivariable Models of In-Hospital Out
Outcome Insurance Private/HMO
In-hospital death Medicaid 0.99 (0.86–
Medicare 1.27 (1.11–
None/UTD 0.68 (0.51–
Length of stay (ratio of means) Medicaid 1.05 (1.01–
Medicare 1.09 (1.06–
None/UTD 1.01 (0.96–
Values are OR (95% CI). *All multivariate models were adjusted for patient characteristics as in T
istribution. The estimatedmean difference of log (length of stay) between groups, and the end poin
he reported numbers are equivalent to the ratio of geometric means, and its confidence interval
Abbreviations as in Tables 1 and 2.cans, including an expansion of Medicaid eligibility.Study limitations. First, although insurance status was col-
lected and analyzed, there were no direct measures of socio-
economic status or mechanism to conclude why certain higher
priced interventions were not advocated. For example, refusal
because of inability to pay may have been present and might
have affected the results. Second, the lack of follow-up after
discharge does not allow assessment of long-term outcomes.
Third, data were collected by medical chart review and depend
on the accuracy and completeness of documentation and
abstraction. Although contraindications and intolerance to
medications were recorded as documented in the medical
record, there may have been patients with contraindications or
intolerances to treatments that were present but not docu-
mented, particularly for less well established quality measures.
Given the observational nature of the study, residual measured
and unobserved variables may have confounded the results.
Although the generalized estimating equations multivariate
analyses adjusted for multiple baseline differences, selection
bias influencing physicians’ and patients’ decision making may
influence these findings. Furthermore, although this was a
registry-based study with an opportunity to study patients in
the real-world setting, data collection was dependent on the
voluntary participation of hospitals, such that findings may not
be generalizable to hospitals that differ in care patterns or
patient characteristics. Additionally, although it is likely that
socioeconomic status correlates with insurance type, this study
could not distinguish whether these findings were influenced
by payment model, socioeconomic status, or both. Finally,
because of the large number of patients in this study, small
differences might have led to statistical significance but lack
clinical relevance.
Conclusions
Using data from the GWTG-HF quality program, the
results of this study suggest that the implementation of
guideline-endorsed HF therapy and in-hospital outcomes
are associated with payer status, with decreased quality and
outcomes in patients with no insurance and those on
Medicaid and Medicare compared with those with private/
HMO insurance. Addressing these differences in care and
t Sources by Payment Source
variate Multivariate
r p Value Private/HMO/Other* p Value
0.85 1.22 (1.06–1.41) 0.0070
0.0007 0.98 (0.86–1.11) 0.74
0.010 1.32 (0.99–1.76) 0.062
0.022 1.04 (1.01–1.08) 0.020
0.0001 1.05 (1.02–1.07) 0.0006
0.74 1.08 (1.04–1.13) 0.0004
Log transformation was used for the length-of-stay analysis to achieve an approximately normal
e confidence interval for the difference, were transformed back by exponentiating. Mathematically,
en the groups.ymencome
Uni
/Othe
1.13)
1.46)
0.91)
1.09)
1.11)
1.05)
able 2.
ts of thoutcomes will require additional efforts.
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